Plain-language summaries of the published research on each compound we carry, with links to every source. The summaries describe what studies reported, what kind of study it was (human, animal or cell), and where the evidence is thin.
- 2,213research records catalogued
- 12compounds and blends
- 294registered trials tracked (ClinicalTrials.gov)
- 778animal-study records
How the library was built
- Sources: PubMed (NCBI E-utilities), ClinicalTrials.gov (API v2), and Europe PMC records that are not in PubMed, such as preprints, theses and non-English abstracts. Records were retrieved in November 2026.
- Every record is linked: each entry carries its PMID, DOI or NCT number. Nothing in the catalog was written from memory.
- Study types: records are grouped as human randomized trials (including registry entries), other human studies, animal, in vitro, reviews, systematic reviews and other (chemistry, analytical, commentary). Labels were classified from abstracts and are spot-checked before quoting.
- Body’s own levels vs. administration: for naturally occurring molecules (Thymosin β4, MOTS-c, NAD+, GHK), many human papers measure the body’s own levels rather than testing the compound. The summaries call this out.
- Blends: blend entries (Wolverine, GLOW) repeat papers from their component entries, so totals across compounds count those papers more than once.
- What the summaries leave out: dosing, protocols and any suggestion of human use. They describe published findings only.
Compounds
*Human RCT counts include ClinicalTrials.gov entries with randomized allocation. Total human-study records across the catalog: 304 randomized, 320 other.
BPC-157
243 catalogued records
Mostly rat injury-model studies; three small uncontrolled human pilots.
- 3 human RCT*
- 8 human other
- 156 animal
- 3 in vitro
- 55 reviews
- 4 registered trials
TB-500 / Thymosin β4
332 catalogued records
Clinical trials of full-length Tβ4; no human trials of the TB-500 fragment.
- 28 human RCT*
- 69 human other
- 117 animal
- 17 in vitro
- 80 reviews
- 20 registered trials
Wolverine (BPC-157 + TB-500)
14 catalogued records
One rat study of the combination; the rest are reviews.
- 0 human RCT*
- 2 human other
- 1 animal
- 0 in vitro
- 10 reviews
- 0 registered trials
GHK-Cu
226 catalogued records
Topical human studies; rodent and cell wound-healing work.
- 4 human RCT*
- 15 human other
- 76 animal
- 33 in vitro
- 19 reviews
- 2 registered trials
Retatrutide
249 catalogued records
Large phase 2 and phase 3 randomized trials; investigational.
- 40 human RCT*
- 24 human other
- 19 animal
- 1 in vitro
- 131 reviews
- 34 registered trials
MOTS-c
274 catalogued records
Mouse studies; human records measure the body’s own MOTS-c.
- 5 human RCT*
- 53 human other
- 109 animal
- 5 in vitro
- 56 reviews
- 3 registered trials
Tesamorelin
114 catalogued records
Phase 3 randomized trials behind an FDA-approved indication.
- 38 human RCT*
- 23 human other
- 5 animal
- 1 in vitro
- 28 reviews
- 21 registered trials
CJC-1295 + Ipamorelin
78 catalogued records
Phase 1–2 data for each compound; no combination studies.
- 6 human RCT*
- 2 human other
- 31 animal
- 3 in vitro
- 12 reviews
- 3 registered trials
Semax
211 catalogued records
Mostly Russian animal studies; small Russian clinical series.
- 1 human RCT*
- 20 human other
- 155 animal
- 6 in vitro
- 12 reviews
- 0 registered trials
Selank
68 catalogued records
Russian rodent studies; a handful of small Russian clinical series.
- 2 human RCT*
- 4 human other
- 54 animal
- 0 in vitro
- 2 reviews
- 0 registered trials
NAD+
398 catalogued records
Mostly precursor (NR/NMN) trials; few studies of direct NAD+.
- 177 human RCT*
- 100 human other
- 55 animal
- 2 in vitro
- 60 reviews
- 207 registered trials
GLOW (BPC-157 + TB-500 + GHK-Cu)
6 catalogued records
No primary studies of the combination; six review articles.
- 0 human RCT*
- 0 human other
- 0 animal
- 0 in vitro
- 6 reviews
- 0 registered trials